CARsgen Therapeutics Holdings (2171) Stock Overview
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2171 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CARsgen Therapeutics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$24.35 |
| 52 Week High | HK$25.60 |
| 52 Week Low | HK$2.48 |
| Beta | 0.50 |
| 1 Month Change | 5.18% |
| 3 Month Change | 62.55% |
| 1 Year Change | 452.15% |
| 3 Year Change | 57.10% |
| 5 Year Change | n/a |
| Change since IPO | -18.83% |
Recent News & Updates
Recent updates
Is CARsgen Therapeutics Holdings (HKG:2171) Weighed On By Its Debt Load?
Dec 04
Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?
Aug 31CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans
Jan 23Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth
Sep 05Shareholder Returns
| 2171 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.0% | 7.8% | 2.2% |
| 1Y | 452.2% | 157.3% | 38.6% |
Return vs Industry: 2171 exceeded the Hong Kong Biotechs industry which returned 153.5% over the past year.
Return vs Market: 2171 exceeded the Hong Kong Market which returned 36.9% over the past year.
Price Volatility
| 2171 volatility | |
|---|---|
| 2171 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 15.4% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2171's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2171's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 465 | Zonghai Li | www.carsgen.com |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence.
CARsgen Therapeutics Holdings Limited Fundamentals Summary
| 2171 fundamental statistics | |
|---|---|
| Market cap | HK$13.48b |
| Earnings (TTM) | -HK$873.20m |
| Revenue (TTM) | HK$43.13m |
Is 2171 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2171 income statement (TTM) | |
|---|---|
| Revenue | CN¥39.43m |
| Cost of Revenue | CN¥24.68m |
| Gross Profit | CN¥14.75m |
| Other Expenses | CN¥812.88m |
| Earnings | -CN¥798.13m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 37.41% |
| Net Profit Margin | -2,024.43% |
| Debt/Equity Ratio | 8.4% |
How did 2171 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 02:09 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CARsgen Therapeutics Holdings Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Ziyi Chen | Goldman Sachs |
| Anita Wei | UBS Investment Bank |